BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  Employer Resources

  How Will AI Impact the Future of Talent Acquisition?

  BioSpace spoke to talent acquisition leaders about how they think artificial intelligence will shape the future of their function.

  October 15, 2024

   · 

  5 min read

   · 

  Chantal Dresner
• 

  Business

  Regeneron and Sanofi’s Dupixent Tipped to Dominate COPD Biologics Market

  Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into significant sales, with GlobalData predicting Dupixent’s COPD revenues will top $6.5 billion within 10 years.

  October 15, 2024

   · 

  3 min read

   · 

  Nick Paul Taylor
• 

  Business

  Vanda Rejects Another Acquisition Offer From Cycle, Affirms Confidence in Business

  Cycle’s second unsuccessful takeover bid comes on the heels of the FDA denying approval for Vanda’s tradipitant, which was being proposed for the treatment of gastroparesis.

  October 15, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Immunology and inflammation

  Jasper Posts Promising Mid-Stage Data for Urticaria Drug, Eyes Challenge to Blockbusters

  With positive results for patients with the chronic skin condition, Jasper Therapeutics’ briquilimab is looking to take on Novartis and Genentech’s Xolair as well as Sanofi and Regeneron’s Dupixent.

  October 15, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Inflammatory bowel disease

  Lilly’s Omvoh Beats J&J’s Stelara in Head-to-Head Phase III Crohn’s Disease Trial

  At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting better long-term outcomes than Johnson & Johnson’s blockbuster therapy Stelara.

  October 15, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  J&J Gets Q3 Beat, Raises Full-Year Guidance on Strong Darzalex Sales

  Sales of Johnson & Johnson’s oncology drugs jumped nearly 19% in the third quarter, driven by cancer treatment Darzalex which brought in more than $3 billion.

  October 15, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Biora Therapeutics Announces Funding Agreement with Existing Investors

  October 15, 2024

   · 

  4 min read
• Press Releases

  Triumvira Immunologics Announces Publication Demonstrating the Safety and Efficacy of TAC T Cells Targeting Claudin 18.2 in Solid Tumors

  October 15, 2024

   · 

  4 min read
• Press Releases

  Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program

  October 15, 2024

   · 

  7 min read
• Press Releases

  Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

  October 15, 2024

   · 

  4 min read